Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury

Qiang Luo; Wei Sun; Zhibo Li; Jinfeng Sun; Yu Xiao; Jichang Zhang; Cuilin Zhu; Bin Liu; Jianxun Ding

doi:10.1016/j.biomaterials.2023.122368

Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury

Biomaterials. 2023 Dec:303:122368. doi: 10.1016/j.biomaterials.2023.122368. Epub 2023 Oct 30.

Authors

Qiang Luo¹, Wei Sun², Zhibo Li³, Jinfeng Sun⁴, Yu Xiao¹, Jichang Zhang³, Cuilin Zhu⁵, Bin Liu⁶, Jianxun Ding⁷

Affiliations

¹ Department of Cardiology, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
² Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China.
³ Department of Cardiology, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China.
⁴ Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
⁵ Department of Cardiovascular Surgery, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China.
⁶ Department of Cardiology, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China. Electronic address: lbin99@jlu.edu.cn.
⁷ Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China; State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 220 Handan Road, Shanghai 200433, PR China. Electronic address: jxding@ciac.ac.cn.

PMID: 37977009
DOI: 10.1016/j.biomaterials.2023.122368

Abstract

Reperfusion therapy is widely used to treat acute myocardial infarction. However, its efficacy is limited by myocardial ischemia-reperfusion injury (MIRI), which occurs paradoxically due to the reperfusion therapy and contributes to the high mortality rate of acute myocardial infarction. Systemic administration of drugs, such as antioxidant and anti-inflammatory agents, to reduce MIRI is often ineffective due to the inadequate release at the pathological sites. Functional biomaterials are being developed to optimize the use of drugs by improving their targetability and bioavailability and reducing side effects, such as gastrointestinal irritation, thrombocytopenia, and liver damage. This review provides an overview of controlled drug delivery biomaterials for treating MIRI by triggering antioxidation, calcium ion overload inhibition, and/or inflammation regulation mechanisms and discusses the challenges and potential applications of these treatments clinically.

Keywords: Controlled drug release; Functional biomaterial; Reduction of reactive oxygen species; Regulation of calcium ion-channel; Regulation of inflammation; Treatment of myocardial ischemia-reperfusion injury.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antioxidants / therapeutic use
Humans
Myocardial Infarction*
Myocardial Reperfusion Injury* / drug therapy

Substances

Antioxidants